Mount Sinai receives $500,000 SU2C grant to explore therapies for lung cancer patients with KRAS mutations

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Mount Sinai is leading a team of lung cancer researchers that has been awarded a three-year, $500,000 grant from Stand Up To Cancer to explore therapeutic approaches to lung tumors with mutations in the KRAS gene, an undertaking that could have a significant impact for a large population of cancer patients who currently lack effective treatment options.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login